Yonathan Lissanu, MD, PhD
Department of Thoracic and Cardiovascular Surgery, Division of Surgery
About Dr. Yonathan Lissanu Deribe
My long-term career goal is to understand the molecular basis of lung cancers with genomic alterations in chromatin and epigenetic regulators and make an impact through identification of therapeutically relevant vulnerabilities in such tumors. I have extensive training and experience in cancer functional genomics under multiple institutions and proven track record of productivity. Hence, I have the expertise and deep motivation to successfully carry out the proposed research project. Currently, the research in my laboratory is focused on two major projects:
-
Identification of therapeutically relevant vulnerabilities in SWI/SNF chromatin remodeling complex mutant lung cancer including clinically applicable combinations for faster translation. Genomic studies have identified frequent mutations in the SWI/SNF complex (~20% of all human tumors). However, our understanding of how these mutations cause cancer is rudimentary. Furthermore, there are no therapies approved for targeting cancer with mutations in this complex. By developing a novel GEM model to study this complex in vivo and coupling it to analysis of human tumors, I have identified metabolic rewiring and dependence on oxidative phosphorylation of SWI/SNF mutant lung cancer. Importantly, I have demonstrated that SWI/SNF mutants are exquisitely sensitive to a newly discovered OXPHOS inhibitor. These observations are recently published in Nature Medicine.
Lissanu Deribe Y , Sun Y, Khan F, Peng Q, Marszalek J, Futreal AP. Mutations in the SWI/SNF complex induce metabolic rewiring and dependence on oxidative phosphorylation. Nat Med 24(7):1047-1057, 7/2018. PMID: 29892061. PMCID: PMC6650267
-
Leveraging my biochemical training and experience in the field of ubiquitination, I am also leading an effort to design, synthesize and characterize bifunctional small molecules, also known as proteolysis targeting chimeras (PROTACs) that induce ubiquitination and degradation of target proteins against a variety of cancer relevant targets. This project is in close collaboration with medicinal chemists at the Pharmaceutical Chemistry Core Facility (PCF) of MD Anderson. Proving my capacity to lead such a project, we have already successfully developed potent PROTACs that induce the degradation of the glucocorticoid receptor (GR). GR is emerging as a major mechanism of drug resistance in multiple cancer types. The Technology Commercialization office of MD Anderson has recently filed patent application for our GR PROTACs ( # PCT/US19/27163) where I am an inventor .
Present Title & Affiliation
Primary Appointment
Assistant Professor, Department of Thoracic and Cardiovascular Surgery - Research, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor (Joint appointment), Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Dual/Joint/Adjunct Appointment
Assistant Professor, Department of Thoracic and Cardiovascular Surgery - Research, The University of Texas MD Anderson Cancer Center, Houston, TX
Assistant Professor (Joint Appointment), Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2010 | Goethe University of Frankfurt, Frankfurt, DE, Biochemistry, Ph.D |
| 2004 | University of Heidelberg, Heidelberg, DE, Molecular and Cellular Biology, M.S |
| 2001 | Gondar College of Medical Sciences (now University of Gondar), Gondar, ET, MD |
Postgraduate Training
| 2011-2015 | Research Fellowship, Prof. Lynda Chin, UT MD Anderson Cancer Center, Houston, Texas |
| 2010-2011 | Research Fellowship, Prof. Lynda Chin, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts |
Experience & Service
Academic Appointments
Instructor, Department of Genomic Med Rsch Department, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2015 - 2019
Assistant Lecturer, Gondar College of Medical Sciences, Gondar, 2001 - 2002
General Medicine Intern, Gondar College of Medical Sciences, Gondar, 2000 - 2001
Institutional Committee Activities
Committee Member, Faculty Recruitment Panel (FRP), 2023 - Present
G&E Program Admissions Subcommittee, Graduate School of Biological Sciences (GSBS), 2022 - Present
Committee Member, Data and Biospecimen Access Committee (DBAC, 2022 - Present
Committee Member, Experimental Therapeutics Department Chair recruitment committee, 2021 - Present
Committee Member, Systems Biology Department Chair Recruitment Committee, 2021 - Present
Honors & Awards
| 2020 | NIH MERIT Award, NIH |
| 2020 | UT Rising STARs Award, The University of Texas |
| 2017 | 1st Annual Science Day Genomic Medicine (1st Place Award), MD Anderson Cancer Center |
| 2016 | Best Poster Award, Symposia on Cancer Research, UT MDACC “Cancer Evolution: Mechanisms of Resistance and Vulnerability, MD Anderson Cancer Center |
| 2013 | Best Poster Award, Symposia on Cancer research “Genomic Medicine”, MD Anderson Cancer Center, MD Anderson Cancer Center |
| 2002 | MCB Fellowship, EMBL, DKFZ and ZMBH |
| 2001 | Best Medical Student Award, Ethiopian Medical Association |
| 1998 | Getachew Bolodia Foundation Fellowship, Getachew Bolodia Foundation, Ethiopia |
Selected Publications
Peer-Reviewed Articles
- Citron F, Ho IL, Balestrieri C, Liu Z, Yen EN, Cecchetto L, Perelli L, Zhang L, Castillo Montanez LA, Blazanin N, Dyke CA, Shah R, Attanasio S, Srinivasan S, Chen KC, Chen Z, Scognamiglio I, Pham N, Khan H, Jiang S, Pan J, Vanderkruk B, Leung C, Mattohti M, Rai K, Chu Y, Wang L, Gao S, Deem AK, Carugo A, Wang H, Yao W, Tonon G, Xiong Y, Lorenzi PL, Bonini C, Zal A, Hoffman B, Giuliani V, Heffernan T, Jeter CR, Lissanu Y, Genovese G, Di Pilato M, Viale A, Draetta GF. WRAD core perturbation impairs DNA replication fidelity promoting immunoediting in pancreatic cancer. bioRxiv, 2025. e-Pub 2025. PMID: 39484624.
- Kotagiri S, Wang Y, Han Y, Liang X, Blazanin N, Nguyen PK, Jiang Y, Lissanu Y. Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors. Journal of Medicinal Chemistry, 2025.
- Kotagiri, S, Blazanin, N, Xi, Y, Han, Y, Qudratullah, M, Liang, X, Wang, Y, Pandey, PR, Mazhar, H, Lam, TA, Singh, A, Wang, J, Lissanu, Y. Enhancer reprogramming underlies therapeutic utility of a SMARCA2 degrader in SMARCA4 mutant cancer. Cell Chemical Biology 31(12):2069-2084.e9, 2024. e-Pub 2024. PMID: 39378885.
- Blazanin N, Liang X, Mahmud I, Kim E, Martinez S, Tan L, Chan W, Anvar NE, Ha MJ, Qudratullah M, Minelli R, Peoples M, Lorenzi P, Hart T, Lissanu Y. Therapeutic modulation of ROCK overcomes metabolic adaptation of cancer cells to OXPHOS inhibition and drives synergistic anti-tumor activity. bioRxiv, 2024. e-Pub 2024. PMID: 39345502.
- Kotagiri S, Wang Y, Han Y, Liang X, Blazanin N, Nguyen PK, Jiang Y, Lissanu Y. Discovery of Novel, Potent and Orally Bioavailable SMARCA2 PROTACs with Synergistic Anti-tumor Activity in Combination with KRAS G12C Inhibitors. bioRxiv, 2024. e-Pub 2024. PMID: 39253520.
- Wang Y, Meraz IM, Qudratullah M, Kotagiri S, Han Y, Xi Y, Wang J, Lissanu Y. SMARCA4 mutation induces tumor cell-intrinsic defects in enhancer landscape and resistance to immunotherapy. bioRxiv, 2024. e-Pub 2024. PMID: 38948751.
- Cai L, Gao Y, DeBerardinis RJ, Acquaah-Mensah G, Aidinis V, Beane JE, Biswal S, Chen T, Concepcion-Crisol CP, Grüner BM, Jia D, Jones R, Kurie JM, Lee MG, Lindahl P, Lissanu Y, Lorz Lopez MC, Martinelli R, Mazur PK, Mazzilli SA, Mii S, Moll H, Moorehead R, Morrisey EE, Ng SR, Oser MG, Pandiri AR, Powell CA, Ramadori G, Santos Lafuente M, Snyder E, Sotillo R, Su KY, Taki T, Taparra K, Xia Y, van Veen E, Winslow MM, Xiao G, Rudin CM, Oliver TG, Xie Y, Minna JD. A Lung Cancer Mouse Model Database. bioRxiv, 2024. e-Pub 2024. PMID: 38464291.
- Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JA. Author Correction: 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol 6(1):608, 2023. e-Pub 2023. PMID: 37280434.
- Meraz IM, Majidi M, Fang B, Meng F, Gao L, Shao R, Song R, Li F, Lissanu Y, Chen H, Ha MJ, Wang Q, Wang J, Shpall E, Jung SY, Haderk F, Gui P, Riess JW, Olivas V, Bivona TG, Roth JA. 3-Phosphoinositide-dependent kinase 1 drives acquired resistance to osimertinib. Commun Biol 6(1):509, 2023. e-Pub 2023. PMID: 37169941.
- Inoue A, Robinson FS, Minelli R, Tomihara H, Rizi BS, Rose JL, Kodama T, Srinivasan S, Harris AL, Zuniga AM, Mullinax RA, Ma X, Seth S, Daniele JR, Peoples MD, Loponte S, Akdemir KC, Khor TO, Feng N, Roszik J, Sobieski MM, Brunell D, Stephan C, Giuliani V, Deem AK, Shingu T, Deribe YL, Menter DG, Heffernan TP, Viale A, Bristow CA, Kopetz S, Draetta GF, Genovese G, Carugo A. Sequential administration of XPO1 and ATR inhibitors enhances therapeutic response in TP53-mutated colorectal cancer. Gastroenterology 161(1):196-210, 2021. e-Pub 2021. PMID: 33745946.
- Tomihara H, Carbone F, Perelli L, Huang JK, Soeung M, Rose JL, Robinson FS, Lissanu Deribe Y, Feng N, Takeda M, Inoue A, Poggetto ED, Deem AK, Maitra A, Msaouel P, Tannir NM, Draetta GF, Viale A, Heffernan TP, Bristow CA, Carugo A, Genovese G. Loss of ARID1A Promotes Epithelial-Mesenchymal Transition and Sensitizes Pancreatic Tumors to Proteotoxic Stress. Cancer Res 81(2):332-343, 2021. e-Pub 2021. PMID: 33158812.
- Akdemir KC, Le VT, Kim JM, Killcoyne S, King DA, Lin Y, Tian Y, Inoue A, Amin S, Robinson FS, Nimmakayalu M, Herrera RE, Lynn EJ, Chan K, Seth S, Klimczak LJ, Gerstung M, Gordenin DA, O’Brien J, Li L, Deribe L, G Verhaak |R, Campbell PJ, Fitzgerald R, Morrison AJ, Dixon JR, Futreal P. Process-specific somatic mutation distributions vary with three-dimensional genome structure. Nature Genetics, 2020. e-Pub 2020.
- Chakravarti D, Hu B, Mao DX, Rashid DA, Li J, Li DJ, Liao DW, Whitley E, Dey DP, Hou P, LaBella K, Chang A, Wang DG, Spring D, Deng P, Zhao D, Liang X, Lan Z, Lin Y, Sarkar DS, Terranova C, Lissanu Deribe Y, Blutt S, Okhuysen DP, Zhang DJ, Vilar DE, Nielsen PO, Dupont A, Younes M, Patel K, Shroyer N, Rai DK, Estes M, Wang Y, Bertuch A. Telomere dysfunction activates YAP1 to drive tissue inflammation. Nature Communications, 2020. e-Pub 2020.
- Lissanu Deribe Y, Sun Y, Terranova C, Khan F, Martinez-Ledesma J, Gay J, Gao G, Mullinax RA, Khor T, Feng N, Lin YH, Wu CC, Reyes C, Peng Q, Robinson F, Inoue A, Kochat V, Liu CG, Asara JM, Moran C, Muller F, Wang J, Fang B, Papadimitrakopoulou V, Wistuba II, Rai K, Marszalek J, Futreal PA. Mutations in the SWI/SNF complex induce a targetable dependence on oxidative phosphorylation in lung cancer. Nat Med 24(7):1047-1057, 2018. e-Pub 2018. PMID: 29892061.
- Lissanu Deribe Y. Interplay between PREX2 mutations and the PI3K pathway and its effect on epigenetic regulation of gene expression in NRAS-mutant melanoma. Small GTPases 7(3):178-85, 2016. e-Pub 2016. PMID: 27111337.
- Lissanu Deribe Y. Mechanistic insights into the role of truncating PREX2 mutations in melanoma. Mol Cell Oncol 3(3):e1160174, 2016. e-Pub 2016. PMID: 27314100.
- Lissanu Deribe Y, Shi Y, Rai K, Nezi L, Amin SB, Wu CC, Akdemir KC, Mahdavi M, Peng Q, Chang QE, Hornigold K, Arold ST, Welch HC, Garraway LA, Chin L. Truncating PREX2 mutations activate its GEF activity and alter gene expression regulation in NRAS-mutant melanoma. Proc Natl Acad Sci U S A 113(9):E1296-305, 2016. e-Pub 2016. PMID: 26884185.
- Atlas Network CG. Genomic classification of cutaneous melanoma. Cell 161(7), 2015. e-Pub 2015.
- Berger MF, Hodis E, Heffernan TP, Deribe YL, Lawrence MS, Protopopov A, Ivanova E, Watson IR, Nickerson E, Ghosh P, Zhang H, Zeid R, Ren X, Cibulskis K, Sivachenko AY, Wagle N, Sucker A, Sougnez C, Onofrio R, Ambrogio L, Auclair D, Fennell T, Carter SL, Drier Y, Stojanov P, Singer MA, Voet D, Jing R, Saksena G, Barretina J, Ramos AH, Pugh TJ, Stransky N, Parkin M, Winckler W, Mahan S, Ardlie K, Baldwin J, Wargo J, Schadendorf D, Meyerson M, Gabriel SB, Golub TR, Wagner SN, Lander ES, Getz G, Chin L, Garraway LA. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature 485(7399):502-6, 2012. e-Pub 2012. PMID: 22622578.
- Ikeda F, Deribe YL, Skånland SS, Stieglitz B, Grabbe C, Franz-Wachtel M, van Wijk SJ, Goswami P, Nagy V, Terzic J, Tokunaga F, Androulidaki A, Nakagawa T, Pasparakis M, Iwai K, Sundberg JP, Schaefer L, Rittinger K, Macek B, Dikic I. SHARPIN forms a linear ubiquitin ligase complex regulating NF-κB activity and apoptosis. Nature 471(7340):637-41, 2011. e-Pub 2011. PMID: 21455181.
- Deribe YL, Pawson T, Dikic I. Post-translational modifications in signal integration. Nat Struct Mol Biol 17(6):666-72, 2010. e-Pub 2010. PMID: 20495563.
- Scharner D, Rössig L, Carmona G, Chavakis E, Urbich C, Fischer A, Kang TB, Wallach D, Chiang YJ, Deribe YL, Dikic I, Zeiher AM, Dimmeler S. Caspase-8 is involved in neovascularization-promoting progenitor cell functions. Arterioscler Thromb Vasc Biol 29(4):571-8, 2009. e-Pub 2009. PMID: 19122169.
- Deribe YL, Wild P, Chandrashaker A, Curak J, Schmidt MH, Kalaidzidis Y, Milutinovic N, Kratchmarova I, Buerkle L, Fetchko MJ, Schmidt P, Kittanakom S, Brown KR, Jurisica I, Blagoev B, Zerial M, Stagljar I, Dikic I. Regulation of epidermal growth factor receptor trafficking by lysine deacetylase HDAC6. Sci Signal 2(102):ra84, 2009. e-Pub 2009. PMID: 20029029.
- Jozic D, Cárdenes N, Deribe YL, Moncalián G, Hoeller D, Groemping Y, Dikic I, Rittinger K, Bravo J. Reply to "The binding stoichiometry of CIN85 SH3 domain A and Cbl-b". Nat Struct Mol Biol 15(9):891-2, 2008. e-Pub 2008. PMID: 18769463.
- Moncalián G, Cárdenes N, Deribe YL, Spínola-Amilibia M, Dikic I, Bravo J. Atypical polyproline recognition by the CMS N-terminal Src homology 3 domain. J Biol Chem 281(50):38845-53, 2006. e-Pub 2006. PMID: 17020880.
- Jozic D, Cárdenes N, Deribe YL, Moncalián G, Hoeller D, Groemping Y, Dikic I, Rittinger K, Bravo J. Cbl promotes clustering of endocytic adaptor proteins. Nat Struct Mol Biol 12(11):972-9, 2005. e-Pub 2005. PMID: 16228008.
Abstracts
- Blazanin N, Liang X, Mahmud I, Kim E, Tan L, Anvar NE, Chan W, Ha MJ, Minelli R, Peoples M, Lorenzi P, Hart T, Lissanu Y, Blazanin N. Therapeutic modulation of rock overcomes metabolic adaption to oxphos inhibition and suppresses tumor growth. AACR Annual Meeting 2024, 2024. e-Pub 2024.
- Kotagiri S, Blazanin N, Qudrattulah M, Xi Y, Wang J, Lissanu Y. Modulation of enhancer accessibility by SMARCA2 PROTACs synergize with TEAD inhibitors to suppress growth of SMARCA4 mutant lung cancers. AACR Annual Meeting 2024, 2024. e-Pub 2024.
- Kotagiri S, Blazanin N, Xi Y, Wang J, Lissanu Y. Novel SMARCA2 degrading bifunctional molecules as therapeutics in SMARCA4 mutant lung cancer. AACR Annual Meeting 2023, 2023. e-Pub 2023.
- Kotagiri S, Blazanin N, Xi Y, Wang J, Lissanu Y. Enhancer reprogramming by novel SMARCA2 degrading PROTACs underlies therapeutic utility in SMARCA4 mutant tumors. AACR Annual Meeting 2023, 2023. e-Pub 2023.
- Link JT, Blazanin N, Deribe YL. Novel glucocorticoid receptor degrading bifunctional molecules as therapeutics in castration-resistant prostate cancer. AACR Annual Meeting 2020, 2020. e-Pub 2020.
Selected Presentations & Talks
Local Presentations
- 2017. Mutations in SWI/SNF chromatin remodeling complex sensitize tumors to OXPHOS inhibition. Conference. Mutations in SWI/SNF chromatin remodeling complex sensitize tumors to OXPHOS inhibition. Houston, TX, US.
- 2012. PREX2 is a novel significantly mutated gene in melanoma. Conference. PREX2 is a novel significantly mutated gene in melanoma. Houston, TX, US.
National Presentations
- 2023. Enhancer reprogramming by novel SMARCA2 degrading PROTACs underlies therapeutic utility in SMARCA4 mutant. Conference. Enhancer reprogramming by novel SMARCA2 degrading PROTACs underlies therapeutic utility in SMARCA4 mutant, US.
- 2020. Novel glucocorticoid receptor degrading bifunctional molecules as therapeutics in castration-resistant prostate cancer. Conference. Novel glucocorticoid receptor degrading bifunctional molecules as therapeutics in castration-resistant prostate cancer, US.
- 2017. Mutations in SWI/SNF chromatin remodeling complex sensitize tumors to OXPHOS inhibition. Conference. Mutations in SWI/SNF chromatin remodeling complex sensitize tumors to OXPHOS inhibition, US.
- 2016. Mutations in SWI/SNF chromatin remodeling complex in lung adenocarcinoma result in metabolic rewiring and sensitivity to inhibition of oxidative phosphorylation. Conference. Mutations in SWI/SNF chromatin remodeling complex in lung adenocarcinoma result in metabolic rewiring and sensitivity to inhibition of oxidative phosphorylation, US.
- 2013. PREX2 integrates PTEN signaling to epigenetic silencing machinery. Conference. PREX2 integrates PTEN signaling to epigenetic silencing machinery. Houston, TX, US.
- 2013. Tumor Microenvironment in Inducible mouse model of Melanoma. Conference. Tumor Microenvironment in Inducible mouse model of Melanoma. Fredericksburg, MD, US.
- 2013. PREX2 couples PTEN signaling to imprinted gene expression in melanoma. Conference. PREX2 couples PTEN signaling to imprinted gene expression in melanoma, US.
Formal Peers
- 2022. Chromatin Remodelers and Transcription Regulators in Cancer: a chemical biology approach. Invited. Chromatin Remodelers and Transcription Regulators in Cancer: a chemical biology approach. Stony Brook, NY, US.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | Selectively targeting cancer survival pathway for lung cancer therapies |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA306803-01/FP00024988 |
| Date: | 2025 - 2027 |
| Title: | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R21CA296248-01A1/FP00021912_Res1 |
| Date: | 2025 - 2030 |
| Title: | Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA299092-01/FP00022929 |
| Date: | 2025 - 2030 |
| Title: | MD Anderson Summer Program in Cancer Research (SPCR) |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | FP00020371_Res1 |
| Date: | 2025 - 2028 |
| Title: | Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas |
| Role: | PI |
| ID: | RP250143/FP00022954 |
| Date: | 2025 - 2026 |
| Title: | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21CA295906 |
| Date: | 2025 - 2026 |
| Title: | Targeting SMARCA2 to overcome Resistance of SMARCA4 Mutant Lung Cancer to KRAS G12C inhibitors |
| Funding Source: | American Cancer Society |
| Role: | PI |
| ID: | 1319991/FP00022192 |
| Date: | 2024 - 2026 |
| Title: | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to immunotherapy |
| Funding Source: | Lung Cancer Research Foundation |
| Role: | PI |
| ID: | 1297662 |
| Date: | 2024 - 2026 |
| Title: | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to KRAS G12C inhibitors |
| Funding Source: | Lung Cancer Research Foundation |
| Role: | PI |
| ID: | 1297650 |
| Date: | 2024 - 2026 |
| Title: | Development of SMARCA2 PROTACs as therapeutics for SMARCA4 mutant tumors |
| Funding Source: | CCSG-MDACC |
| Role: | PI |
| ID: | FY25 IGNITE |
| Date: | 2024 - 2029 |
| Title: | Enhances efficacy of chemotherapy and immunotherapy by targeting multiple PKR mediated pathways in lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00021598 |
| Date: | 2024 - 2026 |
| Title: | Targeting SMARCA2 to overcome resistance of SMARCA4-mutant lung cancer to immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21CA296248 |
| Date: | 2024 - 2029 |
| Title: | The functional and biochemical characterization of the WRAD core in safeguarding genome stability in pancreatic cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | FP00021842 |
| Date: | 2024 - 2027 |
| Title: | LC230377- Novel approaches to enhance immune and therapeutic response in YAP1‐positive recalcitrant lung cancers |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-I |
| ID: | FP00020126 |
| Date: | 2024 - 2029 |
| Title: | Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA288527/FP00019344 |
| Date: | 2024 - 2027 |
| Title: | Understanding and Overcoming Resistance of SMARCA4 Mutant Lung Cancers to Immunotherapy |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP240172 |
| Date: | 2023 - 2028 |
| Title: | Lysosome-targeted therapeutic strategy for lung cancer therapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA285267 |
| Date: | 2022 - 2024 |
| Title: | Investigation of YD23, a novel, potent and selective SMARCA2 degrader, as |
| Funding Source: | Lung Moonshot Program |
| Role: | Co-PI |
| ID: | YD23 |
| Date: | 2022 - 2027 |
| Title: | Targeting SMARCA2 as a therapeutic strategy in SMARCA4 mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01CA272945 |
| Date: | 2022 - 2024 |
| Title: | Targeted Degradation of SMARCA2 as a Therapeutic Strategy in SMARCA4 Mutant Lung Cancers |
| Funding Source: | American Lung Association |
| Role: | PI |
| ID: | 932786 |
| Date: | 2021 - 2024 |
| Title: | METI (MDA Epigenetics Therapeutics Initiative) |
| Funding Source: | MDACC Moon Shot Program |
| Role: | Co-Leader |
| ID: | FY22 Moon Shot Program |
| Date: | 2021 - 2022 |
| Title: | Targeted Proteolytic therapy of Steroid Receptors in Salivary Duct Carcinoma |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | Advisor |
| ID: | FP00011090 |
| Date: | 2021 - 2023 |
| Title: | Metabolic Vulnerabilities of Tumors Containing Extrachromosomal DNA (ecDNA) |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21CA262995 |
| Date: | 2020 - 2021 |
| Title: | Development of a therapeutics discovery pipeline for the treatment of small cell (SCLC) and non-small cell lung cancer (NSCLC) patients |
| Funding Source: | MDACC Moon Shot Program |
| Role: | Co-I |
| ID: | FY21 Lung Moon Shot |
| Date: | 2020 - 2022 |
| Title: | LC190286-Development of the OXPHOS Inhibitor IACS-10759 as Therapeutics in SWI/SNF Mutant Lung Cancer |
| Funding Source: | DOD/Congressionally Directed Medical Research Programs (DOD/CDMRP) |
| Role: | PI |
| ID: | GRANT12920107 |
| Date: | 2020 - 2025 |
| Title: | Advanced mammalian models for identification of novel drug combinations effective for non small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Multi-PI |
| ID: | R01CA255117 |
| Date: | 2020 - 2022 |
| Title: | Targeted Proteolysis of Glucocorticoid Receptor (GR) as a Therapeutic Strategy to Enhance Anti-Tumor Immunity |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP200532 |
| Date: | 2020 - 2027 |
| Title: | Mechanisms and Vulnerabilities of SWI/SNF chromatin remodeling complex mutant lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R37CA251629 |
| Date: | 2020 - 2021 |
| Title: | Novel combination therapies targeting SWI/SNF mutant lung cancer |
| Funding Source: | Lung SPORE |
| Role: | PI |
| ID: | P50CA070907 |
| Date: | 2020 - 2022 |
| Title: | Targeted Proteolysis of Glucocorticoid Receptor as a Therapeutic Strategy to Enhance Anti-Tumor Immunity |
| Funding Source: | Emerson Collective Cancer Research Fund |
| Role: | PI |
| ID: | FP00009582 |
| Date: | 2020 - 2020 |
| Title: | CCSG New Faculty Award |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | P30CA016672-44 |
| Date: | 2020 - 2022 |
| Title: | Targeting Metabolic Vulnerability of SWI/SNF mutant lung cancer |
| Funding Source: | Damon Runyon Cancer Research Foundation |
| Role: | PI |
| ID: | Stage 1 Award |
| Date: | 2019 - 2022 |
| Title: | Therapeutic Targeting of SWI/SNF Mutant Lung Cancer |
| Funding Source: | The University of Texas System |
| Role: | PI |
| Date: | 2019 - 2025 |
| Title: | Assistant Professor Start Up Funds |
| Funding Source: | UTMDACC |
| Role: | PI |
| Date: | 2018 - 2021 |
| Title: | Glucocorticoid Receptor degrading bifunctional molecules as therapeutics in cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R21CA232233 |
| Date: | 2017 - 2019 |
| Title: | Targeted proteolysis of glucocorticoid receptor (GR) as a therapeutic strategy in anti‐androgen treatment resistant prostate cancer |
| Funding Source: | Developmental Research Program (DRP) Award from MD Anderson Prostate Cancer |
| Role: | PI |
| ID: | P50CA140388 |
Patient Reviews
CV information above last modified March 03, 2025